文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

镰状细胞病是儿童移植相关血栓性微血管病的危险因素

Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.
PubMed 文献 · Blood Adv · 2023-01-01

该单中心回顾性研究纳入2015年1月至2020年6月接受首次单倍体或全相合同胞供者造血干细胞移植的115名儿童,其中52例患镰状细胞病。尽管非镰状细胞病队列具有更多移植相关血栓性微血管病危险因素,镰状细胞病组移植相关血栓性微血管病发生率仍显著更高(13% vs 2%,P=0.015),单倍体移植者风险最高。

要点

  • 镰状细胞病患儿移植后移植相关血栓性微血管病发生率为13%(7/52),非镰状细胞病患儿为2%(1/63)(P=0.015)。
  • 单倍体造血干细胞移植者发生移植相关血栓性微血管病的比值比为33(95%CI 1.4-793.2)。
  • 校正HLA匹配、移植物抗宿主病、移植后病毒感染、干细胞来源和清髓后,镰状细胞病仍为移植相关血栓性微血管病的危险因素(OR=12.22,95%CI 1.15-129.6)。

核心结论

  • 镰状细胞病患儿移植后需仔细筛查移植相关血栓性微血管病,尤其是接受单倍体造血干细胞移植者。

研究设计与样本

  • 该研究为经机构审查委员会批准的单中心回顾性研究,纳入2015年1月至2020年6月接受首次单倍体或全相合同胞供者造血干细胞移植的115名儿童,其中52例患镰状细胞病,63例为非镰状细胞病适应症。

主要发现

  • 镰状细胞病组7/52例(13%)发生移植相关血栓性微血管病,非镰状细胞病组1/63例(2%)发生(P=0.015)。
  • 单倍体造血干细胞移植者发生移植相关血栓性微血管病的比值比为33(95%CI 1.4-793.2)。
  • 校正HLA匹配、移植物抗宿主病、移植后病毒感染、干细胞来源和清髓后,镰状细胞病仍为移植相关血栓性微血管病的危险因素(OR=12.22,95%CI 1.15-129.6)。
  • 两组严重3至4级急性移植物抗宿主病无显著差异。
  • 非镰状细胞病队列中巨细胞病毒阳性受者、含放疗预处理方案和外周血干细胞移植物来源显著更多(P≤0.05),这些均为移植相关血栓性微血管病的已知危险因素。

关键数值与推荐

  • 在可获得的移植前样本中,镰状细胞病患者与非镰状细胞病患者补体生物标志物无差异,但镰状细胞病患者内皮活化标志物可溶性血管细胞黏附分子1和P-选择素水平显著更高。

临床怎么用

  • 作者认为,镰状细胞病患儿移植后需仔细筛查移植相关血栓性微血管病,尤其是接受单倍体造血干细胞移植者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) and sickle cell disease (SCD) share features of endothelial and complement activation. Thus, we hypothesized that SCD is a risk factor for TA-TMA and that prehematopoietic cellular transplantation (HCT) markers of endothelial dysfunction and complement activation would be higher in patients with SCD. Children who underwent initial haploidentical or matched sibling donor HCT between January 2015 and June 2020 were included in this institutional review board-approved, single institution, retrospective study. Of the 115 children, 52 had SCD, and 63 underwent HCT for non-SCD indications. There was no significant difference in severe grade 3 to 4 acute graft-versus-host disease (GVHD) between recipients of HCT with or without SCD. The non-SCD cohort had significantly more cytomegalovirus-positive recipients, radiation-containing preparative regimens, and peripheral blood stem cell graft sources (P ≤ .05), all described risk factors for developing TA-TMA. Despite this, 7 of 52 patients (13%) with SCD developed TA-TMA compared with 1 of 63 patients (2%) without SCD (P = .015). Risk was highest in those who underwent haploidentical HCT (odds ratio [OR], 33; 95% confidence interval [CI], 1.4-793.2). Adjusting for HLA match, GVHD, post-HCT viral infection, stem cell source, and myeloablation, SCD remained a risk for developing TA-TMA (OR, 12.22; 95% CI, 1.15-129.6). In available pre-HCT samples, there was no difference in complement biomarkers between those with SCD and those without, though patients with SCD did have significantly higher levels of markers of endothelial activation, soluble vascular cell adhesion molecule 1, and P-selectin. In conclusion, children with SCD merit careful screening for TA-TMA after HCT, particularly those receiving a haploidentical HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schoettler M, Stenger E, Spencer K, et al. Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children. Blood Adv. 2023. PMID: 36075028. doi:10.1182/bloodadvances.2022008058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。